Life Sciences

Amgen, Wyeth sued for alleged illegal marketing

Pharma Compliance Alert, March 4, 2009

A whistleblower lawsuit partially unsealed in Massachusetts accuses Amgen of engaging in illegally marketing Aranesp and Enbrel, according to a Wall Street Journal article.

Wyeth, which co-markets Enbrel in the US and Canada, revealed it was also named in the suit in a filing with the SEC.

Read more about the allegations against Amgen and Wyeth.

    ePharm5 InDepth
  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Healthcare Marketing Advisor

    Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...

  • Needlestick Prevention Training Video

    Highlighting the five most frequent needlestick scenarios, this training video instructs frontline healthcare staff on on...

Most Popular